Adage Capital Partners
CTMX icon

Adage Capital Partners’s CytomX Therapeutics CTMX Stock Holding History

Adage Capital Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,000,000
Closed -$3.54M – 896
2024
Q3 		$3.54M Hold
3,000,000
– – 0.01% 745
2024
Q2 		$3.66M Buy
3,000,000
+1,000,000
+50% +$1.99M 0.01% 739
2024
Q1 		$4.36M Buy
+2,000,000
New +$3.69M 0.01% 709
2022
Q3 		– Sell
-2,000,000
Closed -$3.66M – 1062
2022
Q2 		$3.66M Hold
2,000,000
– – 0.01% 834
2022
Q1 		$5.34M Buy
+2,000,000
New +$7.68M 0.01% 823

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners's CTMX Position: Q4 2024 in Review

Adage Capital Partners sold out of CytomX Therapeutics (CTMX) in Q4 2024, closing a stake of 3,000,000 shares — an estimated $3.54M sold.

Adage Capital Partners first reported a position in CTMX in Q1 2022 and held it in 5 quarters. The position peaked at $5.34M in Q1 2022. 70 funds tracked by Wall St. Rank hold CTMX as of Q4 2024.

  • Adage Capital Partners reported no remaining CytomX Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Adage Capital Partners sold 3,000,000 CytomX Therapeutics shares in Q4 2024, an estimated $3.54M.
  • Adage Capital Partners first reported a position in CytomX Therapeutics in Q1 2022 and held it in 5 quarters.
  • Adage Capital Partners's CytomX Therapeutics position peaked at $5.34M in Q1 2022.
  • 70 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.